2009-11-18

Ukraine Sequences Demonstrate Donations from Argentina Avian H1N1

A substantial portion of the preliminary analysis on the Ukraine, including the count of polymorphisms, has been revised due to cross-validation of the genetic sequences with variant interpretations.

==

Mill Hill released several sequences today into GISAID from the Ukraine.  While we are bound by covenant to secure details until the sequences are publically released, we may provide a high-level analysis that the changes seen are expected, are well within the probabilities we previously defined and that the red-winged Tinamou from Argentina (Avian H1N1) is directly matched as a potential donor on 2 disbursed polymorphisms.

No 225N is observed in the 10 Hemagglutinins, indicating an absence of the D225N polymorphism.  60% of the sequences are wild-type at residue 225, while the remainder are monomorphic, all with the same expected revision.  The highly transmissible nature of these PF11 strains in the Ukraine has been accomplished with only a very slight adjustment in the viral genetics due to the Influenza Flux (zoonotic influx/reflux).  A confused virus is a dangerous organism.

A novel synonymous SNP into the PF11 reservoir occurs in the leading one third of 7 sequences providing a signature for the area.  Our initial survey count indicates a minimum of 20 SNPs, 13 silent, in this small dataset of 10 Hemagglutinins.

One of the boarding school cases in Jiangyin carries a deeply downstream Ukraine and Tinamou polymorphism.  H1N1 Avian SNPs appear 5 times across 4 sequences including 1 set of 2 Tinamou SNPs in a single sequence.

Jiangyin34
Progenitors may include:
red-winged tinamou/Argentina/MP1/2008 H1N1
     with HA 225G, 277N, 286H, 298V, syn413K, 502K / NA 106I, 248N, 286G

We are very interested in the sub-species potentially generated from the donations off the Argentinian bird as you may have read:

Additional analysis will be ongoing and details will be released as the data is vetted for public usage.  Questions continue to surround the clinical data and more will always be appreciated. 

The more important question is, "Where are the other 5 sequences and what criteria were used to select these 10 for publication?"  One point four million cases.  Fifteen samples.  Ten sequences. 

Dataset limitations do apply.


Please visit GeneWurx.com for insight into the latest published studies.

GeneWurx.com